levetiracetam - Resultats de la cerca

Unió Europea - letó - EMA (European Medicines Agency)

breyanzi

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiski līdzekļi - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Unió Europea - letó - EMA (European Medicines Agency)

tepkinly

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiski līdzekļi - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Unió Europea - letó - EMA (European Medicines Agency)

bindren

mitsubishi pharma europe ltd - colestilan - hiperfosfatemija - zāles hiperkaliēmijas un hiperfosfātēmijas ārstēšanai - hiperfosfatēmijas ārstēšana pieaugušiem pacientiem ar hronisku nieru slimību, kurā tiek veikta hemodialīze vai peritoneālā dialīze.

Unió Europea - letó - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - prekursoru šūnu limfoblastiska leikēmija-limfoma - antineoplastiski līdzekļi - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.